Highest-materiality recent filing
Celldex Q2 net loss $73.5M; barzolvolimab Phase 3 CSU topline data expected Sept/Oct 2026
Net loss of $73.5M ($0.94/share) vs $56.6M in Q2 2025; no material revenue.
Celldex Therapeutics CFO Sam Martin to retire by March 31, 2027; search underway
Sam Martin, SVP and CFO, notified of his retirement effective on or about March 31, 2027.
Celldex shareholders OK 3.4M share increase to equity plan; all directors re-elected
Approved 2021 Omnibus Equity Incentive Plan amendment raising share reserve by 3.4M to 12.9M shares.
Celldex completes Phase 3 CSU enrollment 6 months early; raises $345M; Q1 net loss $78.7M
Phase 3 CSU (EMBARQ-CSU1/2) enrolled 1,939 patients, 6 months ahead of guidance; topline data expected Q4 2026, BLA in 2027.
Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch
Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.
Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4
Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.
Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias
Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.
Primary endpoint met: peak mast cell count reduced by -36.0 vs placebo -2.7 (p<0.0001) at Week 12.
Net loss of $56.6M versus $35.8M in Q2 2024; R&D spend rose to $54.2M on barzolvolimab trials.
Celldex shareholders approve equity plan increase, elect directors including Denice Torres
Stockholders approved 2M share increase to 2021 Omnibus Plan (total 9.5M shares) with 53.2M for, 963K against.
Celldex Q1 net loss widens to $53.8M; Phase 3 CSU enrollment ongoing, multiple data readouts in 2025
Net loss of $53.8M ($0.81/share) vs $32.8M ($0.56/share) in Q1 2024; R&D expenses rose to $52.6M.
Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling
Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.
Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints
Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.
Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched
Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.
Celldex shareholders approve 3.2M share increase to equity plan; director award limits raised
Stockholders approved amendment increasing share reserve from 4.3M to 7.5M shares under 2021 Omnibus Plan.
Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024
Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.
Celldex prices upsized $400M common stock offering at $47/share, net proceeds ~$376M
Priced public offering of 8,520,000 shares at $47.00 per share; upsized from initial $250M to $400M.
Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024
Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).
Celldex Therapeutics prices $200.5M public offering of 7.425M shares at $27.00
Offering of 7,425,000 shares at $27.00 per share; underwriters have 30-day option for 1,113,750 additional shares.
Celldex announces positive Phase 2 CSU data for barzolvolimab; $12.5M milestone triggered
Barzolvolimab met primary endpoint: LS mean UAS7 change from baseline to week 12 was -23.87 (300mg q8w) vs -10.47 placebo (p<0.0001).
Celldex Q3 net loss $38.3M ($0.81/shr); Phase 2 CSU enrollment complete, data by YE 2023
Net loss of $38.3M ($0.81 per share) vs $26.8M ($0.57) a year ago; revenue $1.5M.
Celldex Q2 net loss $30.5M ($0.65/sh); Phase 2 CSU enrollment complete, topline by YE 2023
Net loss of $30.5M ($0.65/sh) for Q2 2023 vs $36.0M ($0.77/sh) in Q2 2022; cash $252.7M.
Celldex shareholders elect directors, approve 600K share increase, say-on-pay at 1 year
All 9 director nominees elected; Dr. Garry A. Neil received highest opposition with 6.2M against.
Celldex reports Q1 2023 net loss $29.4M; advances barzolvolimab Phase 2 studies
Q1 2023 net loss $29.4M ($0.62/share); revenue $1.0M (vs $0.2M prior year).
Celldex refutes false report; barzolvolimab PN study continues, Phase 2 subQ planned
Inaccurate report at AAD Annual Meeting stated Celldex terminated Phase 1b barzolvolimab study in prurigo nodularis due to SAE.
Celldex Q4 net loss $26.5M ($0.56/sh); barzolvolimab Phase 2 CSU enrollment to complete by Q3 2023
Net loss of $26.5M ($0.56 per share) for Q4 2022; full year net loss $112.3M ($2.40 per share).
Celldex appoints Rita Jain, M.D. to Board of Directors
Rita Jain, M.D. appointed to Celldex Board effective February 16, 2023.
Celldex reports Q3 2022 net loss of $26.8M; cash $323.5M; barzolvolimab data readouts planned
Net loss per share ($0.57) in Q3 2022 vs ($0.45) in Q3 2021; nine-month net loss ($85.8M) includes $15M litigation settlement.
Celldex Q2 net loss $0.77/sh; barzolvolimab Ph2 studies initiated; settles SRS litigation
Net loss $36M ($0.77/sh) vs $13.4M ($0.34/sh) in Q2 2021; revenue $0.2M down from $3.5M.
Celldex settles Kolltan merger litigation; agrees to up to $80M in milestone payments
Celldex pays $15M upfront; future milestones replaced with $12.5M on successful Phase II of CDX-0159 (barzolvolimab) and $52.5M on first regulatory approval.
Celldex to pay $15M cash upon signing formal settlement agreement; trial set for June 21, 2022 vacated.
All 8 director nominees elected; Karen L. Shoos received 39.9M votes for, 1.0M withheld.
Celldex Q1 net loss $0.49/share; cash $380.5M; barzolvolimab Ph2 starts Q2 2022
Net loss of $23.1M ($0.49 per share) vs $16.5M ($0.42) a year ago; revenue fell to $0.2M from $0.7M.
Celldex Q4 net loss $20.1M; CDX-0159 Phase 2 urticaria studies to start Q2 2022
Net loss of $20.1M ($0.43 diluted EPS) for Q4 2021; full year net loss $70.5M ($1.64 EPS).
Celldex amends bylaws to implement proxy access for shareholders
Board approved proxy access on Jan 25, 2022, adding Article III Section 13 to bylaws.
Celldex reports Q3 net loss of $20.5M, cash $423M, CDX-0159 95% complete response.
Net loss $20.5M ($0.45/share) in Q3 2021; revenue $0.2M, vs net loss $14.2M ($0.36/share) in Q3 2020.
Celldex reports Q2 2021 net loss of $13.4M; raises $287.5M in follow-on offering
Net loss $13.4M ($0.34/share) vs $11.0M ($0.50/share) in Q2 2020; revenue $3.5M vs $0.2M.
Celldex prices upsized $250M public offering at $42/share; net proceeds ~$234.8M
Celldex priced 5,952,381 shares at $42.00 per share in an upsized public offering for $250M gross proceeds.
19 of 19 patients (100%) showed clinical response; 18 of 19 (95%) achieved complete response by provocation testing.
Celldex enters amended employment agreements with 10 executives, new salaries and bonus targets
CEO Marucci base salary $680,908 (60% bonus); CFO Martin $412,820 (40% bonus).
On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.
Rita Jain, M.D. was appointed as a member of our Board of Directors (the “ Board ”) on February 16, 2023.
Max materiality 0.85 · Median 0.68 · Most common event earnings